Perceptual characteristics of tracheoesophageal speech production using the new indwelling Provox Vega voice prosthesis: A randomized controlled crossover trial

Background. The objective of this study was to determine if the design enhancements incorporated into the new Provox Vega Indwelling Voice prostheses result in any positive benefits in vivo. Methods. Using a randomized, crossover study design, 31 participants using tracheoesophageal speech postlaryn...

Full description

Saved in:
Bibliographic Details
Published in:Head & neck Vol. 33; no. 1; pp. 13 - 19
Main Authors: Ward, Elizabeth C., Hancock, Kelli, Lawson, Nadine, van As-Brooks, Corina J.
Format: Journal Article
Language:English
Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01-01-2011
Wiley
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. The objective of this study was to determine if the design enhancements incorporated into the new Provox Vega Indwelling Voice prostheses result in any positive benefits in vivo. Methods. Using a randomized, crossover study design, 31 participants using tracheoesophageal speech postlaryngectomy completed a 3‐week trial of the Provox Vega and a comparator device. Main outcome measures included patient perceptions of vocal effort and quality using each device, and perceptual judgments of voice quality produced. Results. The majority of patients (72%) indicated the Provox Vega gave them overall better voice quality and 52% felt they required less effort to phonate. Voice samples produced with the Provox Vega were also perceived by listeners to be significantly (p < .05) less strained, easier to understand, produced with less effort, and the better speech sample overall. Conclusion. Results support that the aerodynamic improvements incorporated in the design of the new Provox Vega facilitate enhanced voice and speech qualities. © 2010 Wiley Periodicals, Inc. Head Neck, 2011
Bibliography:Conflict of Interest: Corina J. van As-Brooks is working part-time in Atos Medical as Clinical Affairs Manager. Atos Medical is a manufacturer of Provex Vega. She had an active role in project design. She did not participate in data collection and interpretation. Datasets were held by both Atos Medical and the Princess Alexandra Hospital and were analyzed independently by both groups.
ArticleID:HED21389
istex:BD6FC051E350987BCD7CF0AB8B75611EB0A47FBB
ark:/67375/WNG-9JNLNJ8Z-P
This article was published online 31 March 2010. An error was subsequently identified. This notice is included in the online and print versions to indicate that both have been corrected on 13 April 2010.
Conflict of Interest: Corina J. van As–Brooks is working part‐time in Atos Medical as Clinical Affairs Manager. Atos Medical is a manufacturer of Provex Vega. She had an active role in project design. She did not participate in data collection and interpretation. Datasets were held by both Atos Medical and the Princess Alexandra Hospital and were analyzed independently by both groups.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
content type line 23
ISSN:1043-3074
1097-0347
DOI:10.1002/hed.21389